{"preliminary_commentary":{"by_channel":{"x_thread":18,"youtube":8,"podcast":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05361720\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"VICCURO21103","nct_id":"NCT05361720","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=viccuro21103-nct05361720. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"INDUCTION: Patients receive ipilimumab and nivolumab IV on day 1. Cycles repeat every 21 days for 4 cycles.\n\nMAINTENANCE: Patients receive nivolumab IV on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","label":"Arm I (ipilimumab, nivolumab)","type":"EXPERIMENTAL"},{"description":"Patients receive nivolumab IV on day 1 and cabozantinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","label":"Arm II (nivolumab, cabozantinib)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","United States Department of Defense"],"completion_date":{"date":"2028-07-01","type":"ESTIMATED"},"conditions":["Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":{"count":54,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cabozantinib","otherNames":[],"type":"DRUG"},{"name":"Ipilimumab","otherNames":["Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody","BMS-734016","Ipilimumab Biosimilar CS1002","MDX-010","MDX-CTLA4","Yervoy"],"type":"BIOLOGICAL"},{"name":"Nivolumab","otherNames":["BMS-936558","CMAB819","MDX-1106","NIVO","Nivolumab Biosimilar CMAB819","ONO-4538","Opdivo"],"type":"BIOLOGICAL"}],"last_update":"2026-08-19","lead_sponsor":"Vanderbilt-Ingram Cancer Center","official_title":"Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-10-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall response rate (ORR) (Arm 1)","timeFrame":"Up to 4 years"},{"measure":"Overall response rate (Arm 2)","timeFrame":"Up to 4 years"}],"references":[],"start_date":{"date":"2022-12-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study","url":"https://clinicaltrials.gov/study/NCT05361720"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/viccuro21103-nct05361720"}